ArticlePLoS neglected tropical diseases2025
Transitory impact of subclinical Shigella infections on biomarkers of environmental enteropathy in children under 2 years.
Article in PLoS neglected tropical diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Clinical and subclinical Shigella infections among children living in low- and middle-income countries (LMICs) have been associated with long-term adverse effects such as impaired linear growth. The mechanism for the impact of subclinical infections has been theorized to occur through contributions to environmental enteropathy (EE). While Shigella has previously been associated with biomarkers of EE at the time of infection, we evaluated whether this impact was sustained after infections, which would support EE being the mechanism for the effects of Shigella on growth. A prospective birth cohort study of 1,715 children living in 8 different LMICs was conducted. Over the course of 24 months, monthly non-diarrheal stool samples were analyzed for subclinical Shigella infections through quantitative PCR methods. EE was reflected by elevated concentrations of 3 fecal biomarkers: myeloperoxidase (MPO), neopterin (NEO), and alpha-1-antitrypsin (AAT). MPO concentrations were found to be significantly higher by 0.30 ln(nm/mL) (95% CI: 0.23, 0.37) in the initial month of Shigella detection among stools with subclinical Shigella infections. After the Shigella infection, MPO concentrations declined throughout the following 6 months, and concentrations were lower by 6 months post-infection [MPO 6-month difference: -0.16 ln(nm/mL) (95% CI: -0.26, -0.04)]. Subclinical Shigella infections had no effect on NEO concentration levels within the initial month of Shigella detection but did decrease post-infection. Subclinical Shigella infections had no effect on AAT concentration levels until 6 months post-infection [AAT difference: -0.13 ln(mg/g) (95% CI: -0.24, -0.03)]. These findings did not differ by antibiotic use around time of index infection. The impact of Shigella on biomarkers of EE was not sustained, suggesting the negative association between Shigella and growth could be explained by the accumulation of time-limited rather than persistent effects on inflammation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.